Cargando…
P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429549/ http://dx.doi.org/10.1097/01.HS9.0000969408.27108.10 |
| _version_ | 1785090742562062336 |
|---|---|
| author | LI, Caixia Wei, Jia Peng, Liu Huang, He LI, Fei Dong, Yujun Cai, Qingqing Yang, Shenmiao Zhang, Xinyou Zhou, Hui Zhang, Lu Shi, Zaixing Liang, Zhiyu Wu, Binghao Zhou, Keshu Wu, Depei |
| author_facet | LI, Caixia Wei, Jia Peng, Liu Huang, He LI, Fei Dong, Yujun Cai, Qingqing Yang, Shenmiao Zhang, Xinyou Zhou, Hui Zhang, Lu Shi, Zaixing Liang, Zhiyu Wu, Binghao Zhou, Keshu Wu, Depei |
| author_sort | LI, Caixia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429549 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104295492023-08-17 P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES LI, Caixia Wei, Jia Peng, Liu Huang, He LI, Fei Dong, Yujun Cai, Qingqing Yang, Shenmiao Zhang, Xinyou Zhou, Hui Zhang, Lu Shi, Zaixing Liang, Zhiyu Wu, Binghao Zhou, Keshu Wu, Depei Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429549/ http://dx.doi.org/10.1097/01.HS9.0000969408.27108.10 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters LI, Caixia Wei, Jia Peng, Liu Huang, He LI, Fei Dong, Yujun Cai, Qingqing Yang, Shenmiao Zhang, Xinyou Zhou, Hui Zhang, Lu Shi, Zaixing Liang, Zhiyu Wu, Binghao Zhou, Keshu Wu, Depei P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title | P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title_full | P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title_fullStr | P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title_full_unstemmed | P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title_short | P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES |
| title_sort | p626: a phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of bcl-2 inhibitor bgb-11417 in adult patients with mature b-cell malignancies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429549/ http://dx.doi.org/10.1097/01.HS9.0000969408.27108.10 |
| work_keys_str_mv | AT licaixia p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT weijia p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT pengliu p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT huanghe p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT lifei p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT dongyujun p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT caiqingqing p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT yangshenmiao p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT zhangxinyou p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT zhouhui p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT zhanglu p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT shizaixing p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT liangzhiyu p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT wubinghao p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT zhoukeshu p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies AT wudepei p626aphase1studyevaluatingthesafetytolerabilitypharmacokineticsandpreliminaryantitumoractivityofbcl2inhibitorbgb11417inadultpatientswithmaturebcellmalignancies |